WASHINGTON, DC – (December 17, 2008) – The Biotechnology Industry Organization (BIO) today announced the first 80 companies selected through a competitive screening process to present at the Eleventh Annual BIO CEO & Investor Conference. Presenting companies were selected for their potential to deliver on near term clinical catalysts and accomplishments across major therapeutic markets and areas of unmet medical need.
A total of 150 presenting companies will be selected and posted on the conference website on a rolling basis. To view the latest list, please visit http://ceo.bio.org. Leading public biotech companies were chosen using metrics developed by BIO’s internal Industry Analysis team and were further vetted by an Advisory Committee, comprised of members from top tier investment firms:
• Ben Perkins, Pacific Growth Equities, LLC • Kelly Lisbakken, Pacific Growth Equities, LLC • Mike King, Rodman & Renshaw • David Kroin, Great Point Partners, LLC • David Nikodem, BNP Paribas • Ryan Ogg, Visium Asset Management, LLC • Eric Schmidt, Cowen & Company, LLC • Mark Schoenbaum, Deutsche Bank Securities, Inc
“These leading companies represent the industry’s most promising investment opportunities with late stage clinical pipelines, well & established business strategies or strong M&A potential,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “Selected companies are also distinguished by significant opportunities for value creation with near term clinical, regulatory and corporate catalysts that will help to support our industry through the current economic downturn.”
Now in its eleventh year, BIO CEO & Investor Conference is the largest independent investor conference for the life sciences industry focused on publicly‐traded biotechnology companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior executives from leading global pharmaceutical and biotechnology companies have the opportunity to shape the future investment landscape of the biotechnology industry. This year’s meeting will also feature issue oriented plenary sessions, company presentations and educational sessions focused on business trends and hot therapeutic areas in life sciences. The conference will also feature BIO’s web based partnering system to arrange one‐on‐one meetings between registered companies, investors, and industry business development, licensing and therapeutic franchise heads.
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit http://ceo.bio.org. Registration is complimentary for qualified investors and credentialed members of the media.
The following companies will present at the Eleventh Annual BIO CEO & Investor Conference:
4SC AG (VSC) Abcam PLC (ABC.L) Ablynx N.V (ABLX.BR). ACADIA Pharmaceuticals, Inc (ACAD) Addex Pharmaceuticals S.A. (ADXN.SW) Advanced Life Sciences Inc. (ADLS) Alexza Pharmaceuticals, Inc (ALXA) Allon Therapeutics, Inc (NPC.TO) Allos Therapeutics Inc. (ALTH) Alnylam Pharmaceuticals, Inc (ALNY) Anadys Pharmaceuticals, Inc (ANDS) Antisoma PLC (ASM.L) Arena Pharmaceuticals Inc. (ARNA) Array BioPharma Inc. (ARRY) AVI BioPharma Inc. (AVII) BioMimetic Therapeutics, Inc (BMTI) BioSante Pharmaceuticals, Inc (BPAX) BTG PLC (BTGGF.PK) Cadence Pharmaceuticals Inc. (CADX) Cell Therapeutics (CTI) CERUS CORP (CERS) Chelsea Therapeutics, Inc (CHTP) ChemGenex Pharmaceuticals, Ltd (CXSP) CombinatoRx, Inc. (CRXX) Cougar Biotechnology Inc. (CGRB) CuraGen Corp. (CRGN) Cyclacel Pharmaceuticals, Inc (CYCC) Cytokinetics Inc. (CYTK) Cytos Biotechnology AG (CYTN.SW) CytRx Corporation (CYTR) Dendreon Corp. (DNDN) Depomed, Inc (DEPO) Dyax Corp. (DYAX) Enzon Pharmaceuticals Inc. (ENZN) EpiCept Corporation (EPCT) Galapagos N.V. (GLPG.BR) Genaera Corporation (GENR) Genta Inc. (GNTA) GeoVax Labs Inc. (GOVX) Geron Corp. (GERN) Gilead Sciences Inc. (GILD) GTC Biotherapeutics Inc. (GTCB) GTx Inc. (GTXI) Icagen, Inc. (ICGN) Idera Pharmaceuticals Inc. (IDRA) Immunogen Inc. (IMGN) Inspire Pharmaceuticals Inc. (ISPH) Karo Bio AB (KARO.ST) Ligand Pharmaceuticals Inc. (LGND) MannKind Corp. (MNKD) MediGene AG (MDGEF.PK) Medivation Inc. (MDVN) Medivir AB (MVR.DE) Micromet Inc. (MITI) Molecular Insight Pharmaceuticals Inc. (MIPI) Momenta Pharmaceuticals Inc. (MNTA) MorphoSys AG (MOR.DE) Neuralstem Inc. (CUR) Newron Pharmaceuticals S.p.A. (NWRN.SW) NicOx S.A. (COX.PA) Novavax Inc. (NVAX) NPS Pharmaceuticals Inc. (NPSP) Oncothyreon Inc. (ONTY) Poniard Pharmaceuticals Inc. (PARD) Rigel Pharmaceuticals Inc. (RIGL) RXI Pharmaceuticals Corp. (RXII) Shire PLC (SHPGY) Spectrum Pharmaceuticals Inc. (SPPI) StemCells Inc. (STEM) Sunesis Pharmaceuticals, Inc (SNSS) SUPERGEN INC (SUPG) Synta Pharmaceuticals Corp. (SNTA) Targacept Inc. (TRGT) Targanta Therapeutics Corp. (TARG) Thrombogenics N.V. (THR.BR) ViroPharma Inc. (VPHM) VIVUS Inc. (VVUS) Wilex AG (WL6.DE) XOMA Ltd. (XOMA)
BIO CEO & Investor Conference Sponsors BIO is pleased to acknowledge the leadership provided by the BIO CEO & Investor Conference sponsors, including Lead Bank Sponsor Pacific Growth Equities, LLC and Host Bank & BIO Helix Sponsor Rodman & Renshaw.
About BIO BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry‐leading investor and partnering meetings held around the world.
Market Data 
Markets 
AI
